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Abstract
Objective- This study investigated whether differences exist in atherogen-induced migratory
behaviors and basal antioxidant enzyme capacity of vascular smooth muscle cells (VSMC)
from human coronary (CA) and internal mammary (IMA) arteries.
Methods- Migration experiments were performed using the Dunn chemotaxis chamber. The
prooxidant [NAD(P)H oxidase] and antioxidant [NOS, superoxide dismutase, catalase and
glutathione peroxidase] enzyme activities were determined by specific assays.
Results- Chemotaxis experiments revealed that while both sets of VSMC migrated towards
platelet-derived growth factor-BB (1-50 ng/ml) and angiotensin II (1-50 nM), neither
oxidized-LDL (ox-LDL, 25-100 g/ml) nor native LDL (100 g/ml) affected chemotaxis in
IMA VSMC. However, high dose ox-LDL produced significant chemotaxis in CA VSMC
that was inhibited by pravastatin (100 nM), mevastatin (10 nM), losartan (10 nM), enalapril
(1 M), and MnTBAP (a free radical scavenger, 50M). Microinjection experiments with
isoprenoids i.e. geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP)
showed distinct involvement of small GTPases in atherogen-induced VSMC migration.
Significant increases in antioxidant enzyme activities and nitrite production along with
marked decreases in NAD(P)H oxidase activity and O2.- levels were determined in IMA
versus CA VSMC.
Conclusions- Enhanced intrinsic antioxidant capacity may confer on IMA VSMC resistance
to migration against atherogenic agents. Drugs that regulate ox-LDL or angiotensin II levels
also exert antimigratory effects.
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3Introduction
Coronary atherosclerosis, associated with oxidative stress, is the leading cause of morbidity
and mortality in developed countries. Atherogenesis, a progressive process ultimately leads to
formation of focal atherosclerotic plaques in the intima, characterized by foam cell formation
and accelerated vascular smooth muscle cell (VSMC) proliferation and migration [1]. Low-
density-lipoprotein (LDL)-cholesterol is a strong predictor of coronary artery disease and the
HMG-CoA reductase inhibitors (statins) reduce the risk of primary and secondary events
[2,3].
Statins are associated with other biological processes in the vessel wall, for example,
simvastatin has been implicated in inhibiting platelet-derived growth factor (PDGF)-induced
DNA synthesis in human glomerular mesangial cells [4]. PDGF secreted by macrophages
exacerbates atherogenesis by stimulating VSMC proliferation and plaque neovascularisation
[1]. Another non-lipid-lowering effect of statins is their ability to prevent migration of VSMC
to PDGF by blocking isoprenoid production. Isoprenoids, like cholesterol, are HMG-CoA
reductase pathway products and are required for prenylation of small monomeric GTPases,
such as Ras and Rho, involved in cell migration control [5]. Hence, the inhibition of PDGF-
induced mitogenesis and migration by statins should limit its deleterious effects.
Angiotensin II (Ang II) which exerts numerous effects on the cardiovascular system
including the induction of VSMC migration, has also been implicated in atherogenesis [6].
Recent studies have revealed that angiotensin converting enzyme inhibitors (ACEI) reduce
the risk of vascular diseases such as myocardial infarction and that Ang II type 1 receptor
(AT1R) blockers (ARB) exert anti-atherosclerotic effects [7,8].
Ang II displays its proatherogenic effects through AT1R stimulation and as a consequence
NAD(P)H oxidase enzyme activation to generate excess levels of superoxide anion (O2.-), a
reactive oxygen species (ROS) [9]. The effects of ROS range from oxidizing LDL and
4eliciting vasoconstriction to scavenging nitric oxide (NO), the most potent endogenous
vasodilator that is produced from L-arginine by NO synthase (NOS) [10,11]. Under
physiological conditions, O2.- is converted to H2O2 by superoxide dismutases (SOD) which is
then further metabolized to H2O by catalase and glutathione peroxidase (GPx) [12]. However,
in pathological conditions, O2.- may lead to atherosclerotic plaque formation via diminished
concentrations and/or aberrant regulation of antioxidant enzymes.
Compared to coronary arteries (CA), human internal mammary arteries (IMA) rarely
develop macroscopic atherosclerotic plaques despite their exposure to similar levels of
atherogenic agents [13]. Therefore, IMA are considered as the best conduits for coronary
bypass grafting. Indeed, IMA grafts have better patency rates compared to other arterial and
venous grafts [13]. Although IMA are possibly not exposed to the same haemodynamic
conditions and turbulence because of their anatomical location, it is reasonable to hypothesize
that the absence of atherosclerotic plaques cannot solely be attributed to their location.
Since VSMC migration is a key factor in atherogenesis, the current study investigated first
whether differences exist in the migratory patterns of CA versus IMA VSMC in the presence
of agents associated with atherogenesis, namely native LDL, oxidized-LDL (ox-LDL), Ang II
or PDGF-BB. Secondly, it investigated how cell migration was altered by free radical
scavengers, molecules that specifically block receptors (CD36, AT1R and PDGF-βR), and
statins. Thirdly, it explored the involvement of small monomeric GTPases to identify
potential differences in CA and IMA VSMC migratory responses. Finally, it examined the
putative differences in basal activity of prooxidant (NAD(P)H oxidase) and antioxidant
(NOS, SOD, catalase and GPx) enzymes as well as nitrite and O2.- production in these cell
types.
Materials and Methods
Patient Characteristics
5IMA samples were collected from patients (n=12) undergoing coronary bypass grafting.
Patients with hypertension (>140/90 mmHg), diabetes mellitus, hypercholesterolemia (>5.2
mM) and smoking within the past 6 months were excluded. Study was approved by the
Research Ethics Committee of the Queen’s University Belfast and protocol conformed to
ethical guidelines of Declaration of Helsinki.
Human IMA VSMC Isolation and Culture
Under sterile conditions, the distal straight (area before the bifurcation) segments of human
IMA were cleaned of adhering tissues and cut open longitudinally prior to denudation of
endothelium and dissection of small squares (~5 mm) to be placed for 30 min in smooth
muscle growth medium 2 (SMGM2, Clonetics, UK) supplemented with
antibiotic/antimycotic agents. Ten explants were placed with vessel lumens down in cell
culture dishes previously wetted with 1.5 ml fetal calf serum. Subsequently 3 ml of SMGM2
was added into dishes and they were placed in a 37oC incubator with growing surface
uppermost. The dishes were inverted 3 days later and the culture medium was changed every
two days.
To obtain normal coronary arteries from patients undergoing cardiac surgery is not
ethically possible, hence normal i.e. genetically unaltered human CA VSMC (n=4 donors)
were purchased from BioWhittaker (UK) and cultured as above in SMGM2. However,
attention was paid to the donors’ characteristics (age, sex and the cardiovascular disease) in
order to match those of the patients from whom IMA cells were isolated. In this study, only
VSMC between passages 4 and 8 were used.
Characterization of VSMC from Human IMA and CA by Immunocytochemistry
IMA or CA cells grown on coverslips were rinsed with ice-cold PBS and fixed in 4%
formaldehyde for 20 min at room temperature before permeabilization with 0.1% Triton X-
100. To characterize the cells as SMC they were stained with a monoclonal antibody raised
6against SM -actin for 1 h in the dark at 4oC prior to mounting in Vectashield and
examination by confocal microscopy (Micro Radiance, Bio-Rad, UK). Staining of cells for
von Willebrand factor failed to produce any staining and hence ruled out endothelial cell
contamination (data not shown). Furthermore, the CA cells were previously stained positive
for smooth muscle myosin, calponin and caldesmin by the commercial company.
Preparation of Lipoproteins
Native LDL was isolated from human blood plasma by ultracentrifugation (density 1.019
to 1.063 g/ml) as previously described [14]. Oxidation of LDL was performed by exposure to
CuCl2 (5 M free Cu2+ concentration) in phosphate-buffered saline (PBS) at 37oC for at least
24 h prior to detection of LDL and ox-LDL bands by lipid gel electrophoresis. Oxidation was
terminated by the addition of EDTA (0.5 mg/ml) and LDL preparations were dialyzed by
EDTA buffer. Native LDL and ox-LDL were kept in 50 mM Tris-HCl, 0.15 M NaCl and 2
mM EDTA at pH 7.4 and used within 10 days of preparation.
Migration Assays
Cell migration was assessed by direct observation and recording of cell behavior in
concentrations of recombinant human PDGF-BB (1-50 ng/ml; Insight Biotechnology Ltd.,
UK), Ang II (1-50 nM; Calbiochem), LDL or ox-LDL (25-100 μg/ml) using the Dunn
chemotaxis chamber (Weber Scientific International, Teddington, UK). This apparatus
permits the direction of movement of individual cells to be measured in relation to the
direction of the gradient, as well as the time course to be followed. The apparatus was set up,
filmed by time-lapse computer photography and data analyzed as described previously
[15,16]. The rationale behind all chemotaxis experiments was the same; the potential
chemoattractant was placed in the outer well of the Dunn chamber in addition to the
components that were available in the inner well to rule out the contribution of those other
components. Between the 2 wells cells on an inverted coverslip are exposed to the
7chemoattractant gradient and can be directly filmed for up to 24 h when the gradient will start
to break down. For example, for LDL experiments SMBM was placed in the inner well and
SMBM with varying concentrations (25-100 μg/ml) of ox-LDL or native LDL (100 μg/ml) in
the outer well.
All cells were serum starved for 18 h prior to migration assays to exclude effects
attributable to factors present in serum other than the expected chemoattractant. Experiments
were run for 18 h with a time-lapse interval of 10 min. Minimum of 30 cells from three
independent experiments were analyzed for each study. Where circular histograms are not
shown (Figures 2-5) the proportion of cells migrating towards the growth factor are given as a
percentage of total cells in that field.
Inhibitor experiments
In those experiments where chemical inhibitors were employed the inhibitors were
dissolved in DMSO and added to the medium to be used in both the inner and outer wells of
the Dunn chamber (there was no period of pre-incubation with the inhibitors). The maximum
final DMSO concentration was 1 μl/ml medium; this concentration was chosen for the control
(solvent only) experiments. Inhibitors and concentrations used: The ACEI enalapril (1 μM,
Merck, Sharp & Dohme), the statin pravastatin (100 nM), the statin mevastatin (10 nM), the
rho kinase inhibitor Y-27362 (100 nM; all from Calbiochem), the ARB losartan (10 nM:
Axxora UK Ltd.), the farnesyl transferase inhibitor (FTI) H-D-Trp-D-Met-p-chloro-D-Phe-
Gla-NH2 (2 nM; Bachem, UK), the extracellular antioxidant Tiron (10 μM, Sigma), and the
intracellular antioxidant MnTBAP (10 or 50 μM, A.G. Scientific).
Surface receptor antibody experiments
Cells were seeded on coverslips as described above and exposed to antibodies to the named
surface receptors (CD36 or PDGF-β; R&D System, Minneapolis, MN) 16 h after the onset of
serum starvation. The cells were then set up in the Dunn chamber 2 h later also in the
8presence of the surface receptor antibody. Antibody specificity was assessed by Western blot
experiments of whole cell lysates which produced only the expected bands (data not shown).
Microinjection assay
Approximately 2 x 104 VSMC from CA or IMA were seeded in 25 mm Petri dishes
containing 18-mm square No. 3 glass coverslips (Chance-Propper, UK) etched with a glass
pen on the reverse side to facilitate localization of microinjected cells as described [5]. The
cells on the coverslips were serum starved for 14 h and then exposed to the statin for 2 h
before microinjection. For analysis of migration, all cells within the marked area were
microinjected (InjectMan: Eppendorf AG, Germany) with control antibody (0.1 mg/mL) and
either geranylgeranylpyrophosphate (GGPP) or farnesylpyrophosphate (FPP) peptides (all
from Sigma). The microinjected coverslips were then set up in the Dunn chamber 2 h later
still in the presence of the statin. At the end of the 18 h migration experiment microinjection
confirmation studies were undertaken with immunofluorescent staining of control antibody as
previously described [5,15]. Vehicle only microinjection had no effect on migration or cell
viability.
Measurement of NAD(P)H Oxidase Activity and Detection of O2.- Levels
O2- levels were measured by cytochrome C reduction assays. Briefly, the cells were
collected in Hanks’ balanced salt solution at a density of 20 x 106 cells/ml and incubated with
50 µM cytochrome C for 60 min at 37°C. O2.- generation was measured as the superoxide
dismutase (10 µg/ml)-inhibitable reduction of cytochrome C and monitored as the change in
absorbance at 550 nm using a Cobas-Mira S centrifugal analyzer. Absorbances were recorded
for 12 min with 90 sec intervals and production of O2.- was calculated as pmoles O2.- per 106
cells after subtracting background values measured at 550 nm. NAD(P)H oxidase activity was
measured in similar experiments where the specific inhibitors of indicated ROS-generating
enzymes, i.e. L-NAME (0.1 mM, eNOS), rotenone (50 M, mitochondrial NAD(P)H
9oxidase), allopurinol (100 M, xanthine oxidase) or indomethacin (50 M, cyclooxygenase),
were added to aliquots during 60 min incubation period prior to determining O2.- generation.
Nitrite Detection
Nitrite levels were measured in cellular homogenates using the Nitrate/Nitrite Colorimetric
Assay Kit according to the manufacturer’s instructions (Alexis Corporation, UK).
NOS Activity Assay
NOS activity was determined, in cell homogenates, by monitoring the conversion of [3H]L-
arginine into [3H]L-citrulline with the NOS detect assay kit (Alexis Biochemicals, UK).
Results were expressed as pmol L-citrulline/mg protein/min.
SOD Assay
SOD activity was measured using a protocol dependent upon the inhibition in reduction of
cytochrome C by endogenous SOD in cell homogenates. The superoxide anion, required for
reduction, was generated by a reaction of xanthine-xanthine oxidase (XO). One unit of XO
activity was defined by the amount of homogenate required to inhibit, by 50%, the rate of
cytochrome C reduction. For total SOD assay, 0.1 mM xanthine was dissolved in 50 mM
NaCO3, 0.1 M EDTA buffer. A dilute stock solution was added to a 10 M solution of
cytochrome C, 50 M xanthine and 0.1 mM EDTA to produce a change in absorbance of
0.025/min at 550 nm at pH 10.
Catalase Assay
The activity of catalase was determined in cell homogenates using a method adapted for
automation on the Cobas Fara centrifugal analyzer [17]. Briefly, the activity was determined
by monitoring the decomposition of H2O2 at 240 nm in the presence of methanol which
produces formaldehyde which in turn reacts with Purpald (4-amino-3-hydazino-5-mercapto-
1,2,4-triazole) and potassium periodate to produce a chromophore. Quantification was
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performed in comparison to the results that were obtained with catalase and formaldehyde
standards.
Glutathione Peroxidase (GPx) Assay
The activity of GPx was determined in cell homogenates using a colorimetric method [17].
riefly, a fresh solution containing 0.3 U/ml glutathione reductase, 1.25 mM reduced
glutathione and 0.19 mM NADPH in 50 mM Tris/HCl (pH 7.4) was prepared. Homogenates
of 100 g total protein were added to this solution and incubated for 3 min prior to addition of
12 mM t-butylhydroperoxide to commence the reaction. Absorbances were read at 340 nm
for 4 min. Activities were calculated as nmol glutathione/mg protein/min.
Statistical Analysis
To test for migration (chemotaxis) the Rayleigh test for unimodal clustering of directions
was applied to the data and p <0.01 was chosen as the criterion for rejecting the null
hypothesis of random directionality. Where there was significant unimodal clustering the
mean direction and its 95% confidence interval were calculated and Tukey’s post hoc analysis
was conducted. Results for enzyme activity assays are presented as meanSEM.; statistical
analyses were performed by two-way analysis of variance (ANOVA) followed by Bonferroni-
Dunn’s post hoc analysis. p<0.05 was considered significant.
Results
Effects of LDL oxidation on migration of human CA and IMA VSMC
The response of CA and IMA to physiological and elevated levels of native and ox-LDL
was investigated. Low concentrations (25 μg/ml) of ox-LDL produced random but not
directed migration of CA or IMA cells (Fig. 1A and 1B respectively; p>0.05 for both). With
increase in concentration (50, 75 or 100 μg/ml) ox-LDL had a differential effect on
chemotaxis; that is, it produced directed migration in CA but not in IMA cells (cf. Figs. 1C,
1E and 1G with 1D, 1F and 1H). Native LDL (100 μg/ml) did not have a chemotactic effect
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on either type of VSMC (Fig. 1I and 1J). It would appear that it is not the level of LDL per se
but oxidation which encourages VSMC migration in CA cells.
Effects of ROS-scavengers on ox-LDL-induced migration of human CA VSMC
O2.-, the foundation molecule of all ROS, may be involved in ox-LDL-mediated
chemotaxis. Hence, the migratory properties of CA VSMC were investigated in the presence
of either Tiron (10 M: extracellular antioxidant) or MnTBAP (10 or 50 M: intracellular
antioxidant). Tiron or the lower dose of MnTBAP had no effect on migration to 50 g/ml ox-
LDL (Fig. 2). Only the higher dose of MnTBAP (50 M) inhibited migration in ox-LDL-
treated CA VSMC (p<0.01). Since ox-LDL is known to bind to the CD36 receptor, it was
interesting to show that CD36 antibody could prevent chemotaxis to ox-LDL. The effect was
receptor-specific since non-specific antibody from the same species and immunoglobulin
subgroup as that for CD36 antibody could not mimic the response. O2.- in VSMC is mainly
generated by NAD(P)H oxidase in response to AT1R activation. Both losartan (10 nM), an
ARB and enalapril (1 μM), an ACEI prevented migration to ox-LDL (Fig. 2). The migratory
response of IMA cells to ox-LDL in the presence of antioxidants was not investigated since
no migration occurred to ox-LDL in that cell type.
Effects of Ang II on VSMC migration
Ang II has been shown to have pro-atherogenic effects, partly due to production of the free
radical superoxide anion as a consequence of NAD(P)H oxidase activation [9]. The
chemotactic dose response to Ang II (1-50 nM) was similar for CA and IMA (Fig 3A).
However, it is of interest that while extracellular antioxidant (Tiron) had no effect on
chemotaxis, intracellular antioxidant (MnTBAP) had a differential effect on CA and IMA. A
lower concentration of antioxidant (10 μM MnTBAP) inhibited Ang II-induced chemotaxis in
IMA than in CA, where a higher concentration of MnTBAP was required to inhibit
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chemotaxis. Since Ang II signals mainly through the AT1R in VSMC, it was important to
demonstrate that losartan prevented chemotaxis with Ang II (Fig. 3B).
Effects of PDGF-BB on VSMC migration
PDGF-BB is a well characterized chemotactic factor for VSMC. CA and IMA showed
similar dose responses to PDGF-BB (1-50 ng/ml) with respect to chemotaxis (Fig. 4A). In
contrast to ox-LDL and Ang II, antioxidants had no effect on PDGF-BB-induced VSMC
migration in either CA or IMA. Since PDGF-BB signals mainly through the PDGF-β receptor
in other VSMC [18], it was interesting to show that specific PDGF-β receptor antibody (but
not non-specific control antibody) blocked PDGF-BB-induced chemotaxis in CA and IMA
VSMC. The ARB losartan had no significant effect on PDGF-BB-induced chemotaxis (Fig.
4B).
Effect of statins on CA and IMA VSMC chemotaxis
Mevastatin (10 nM: Fig. 5) or pravastatin (100 nM: data not shown) blocked chemotaxis to
50 g/ml ox-LDL. To investigate if the inhibitory effect of mevastatin was due to alteration in
the prenylation of small GTPases, isoprenoids were reintroduced to the cells by
microinjection techniques. Both sets of cells were microinjected with either
geranylgeranylpyrophosphate (GGPP; responsible for prenylation of Rho family small
GTPases) or farnesylpyrophosphate (FPP; responsible for prenylation of Ras). In CA VSMC
treated with mevastatin, chemotaxis to ox-LDL was restored by FPP but not GGPP
microinjection. As IMA VSMC did not show directed migration to ox-LDL, the effects of
GGPP and FPP were not assessed in these cells (Fig. 5A).
Ang II-induced chemotaxis was blocked by mevastatin in both cell types. These effects
were shown to be dependent on Ras and Rho prenylation in CA and IMA VSMC,
respectively. To confirm these results migratory responses to Ang II were investigated using
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either a Rho-kinase inhibitor (Y-27362) or a farnesyltransferase inhibitor (FTI) in that while
FTI prevented CA VSMC migration, Y-27362 blocked migration in IMA cells (Fig. 5B).
Mevastatin also inhibited migration of both cell types to PDGF-BB. CA VSMC, as was the
case with ox-LDL and Ang II, had chemotaxis restored when microinjected with FPP
indicating a role for Ras prenylation. A Ras-dependence in CA VSMC migration was again
confirmed with the FTI being able to prevent migration to PDGF-BB. In contrast, IMA cells
did not have chemotaxis restored in the presence of either GGPP or FPP (Fig. 5C). Since
neither small GTPase alone restored chemotaxis, it was deemed possible that they might act
synergistically. Indeed, microinjection of both GGPP and FPP into IMA cells in the presence
of mevastatin restored directed migration to PDGF-BB (percentage migrating cells 80%,
p<0.01).
Intrinsic antioxidant levels in human CA and IMA VSMC
Significantly higher levels of antioxidant enzyme activities along with a marked lower
NAD(P)H oxidase activity were detected in IMA VSMC when compared with CA VSMC
(p<0.05, Table 1). The differences in O2.- and nitrite, the stable end-product of NO, levels
were reflective of the differences observed in NAD(P)H oxidase and NOS enzyme activities,
respectively (p<0.05).
Discussion
The major conclusions to be drawn from the current study are that the enhanced intrinsic
capacity of antioxidant enzymes along with reduced bioavailability of O2.-, through
diminished activity of prooxidant NAD(P)H oxidase enzyme, helps to explain the relative
resistance of human IMA VSMC to atherogenic agents-evoked migration compared to their
counterparts from CA. Free radical scavengers that target intracellular O2.- inhibit selectively
Ang II- and ox-LDL-induced but not PDGF-BB-induced chemotaxis of CA and IMA VSMC.
Moreover, statins, ACEI and ARB suppress VSMC migration in addition to their well-known
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effects related to cholesterol-lowering, Ang II synthesis and Ang II function. The statins
attenuate chemotaxis by preventing prenylation of the small monomeric GTPases involved.
LDL-cholesterol accumulates in macrophages residing in the vascular wall and leads to the
formation of foam cells and fatty streaks [19]. In vivo, oxidative modification of LDL occurs
in endothelial cells, VSMC and macrophages within the arterial wall and subendothelial space
[20]. Both native LDL and ox-LDL regulate the expression of chemotactic factors and cell
adhesion molecules and reduce NO bioavailability, the most potent endogenous vasodilator,
and thus lead to atherosclerosis in a time- and concentration-dependent manner [21]. Since
VSMC migration in the arterial wall is a key feature in atherogenesis, the difference in
migratory pattern of VSMC derived from CA and IMA to ox-LDL may in part account for
the resistance of IMA to atherosclerotic disease.
The present study revealed that while native LDL (100 g/ml) or low dose ox-LDL (25
g/ml) had no impact on VSMC chemotaxis, higher concentrations of ox-LDL (50-100
g/ml) produced a selective migration of CA VSMC. The migration of CA VSMC was
abolished when the ox-LDL containing medium was supplemented with statins, losartan or
enalapril. These findings support previous studies showing that (i) higher levels of plasma ox-
LDL are required for the pathogenesis of CA disease and that oxidation of LDL enhances its
atherogenic capacity [20]; (ii) statins inhibit coronary VSMC migration to
lysophosphatidylcholine, a component of ox-LDL [22]; (iii) lowering serum LDL-cholesterol
reduces the risk of cardiovascular events [2,3]; (iv) ARB suppress atherogenesis through
reducing coronary VSMC migration [8]; and (v) ACEI reduce the risk of vascular diseases
including myocardial ischemia [7].
Recent evidence implicate enhanced oxidative stress status (i.e. excess generation and/or
release of ROS, in particular O2.-) in the pathogenesis of coronary atherosclerosis; ROS may
have direct vasoconstrictor effects, have the ability to scavenge NO reducing its
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bioavailability, and stimulate VSMC migration [10,11,23]. Incubation of VSMC with LDL is
associated with excess production of O2.- in a reaction that is coupled to induction of the
AT1R subtype and subsequently activation of the NAD(P)H oxidase enzyme system [9,24]:
that migration to ox-LDL could be blocked by antibody to its main receptor (CD36), an AT1R
antagonist (losartan) and a O2.- scavenger (MnTBAP) in the present work supports those
findings.
Circulating levels of Ang II, the AT1R specific cytokine, are raised in atherogenesis and
may potentiate CA and IMA VSMC motility [6]. PDGF-BB is a powerful mitogenic growth
factor, which is also raised in the environs of a developing atheroma. Both Ang II and PDGF-
BB produced significant chemotaxis in these cell types in the presence of physiological or
elevated concentrations for each agent (≥ 10 nM and 10 ng/ml, respectively). The Ang II-
evoked migration depended on AT1R activation, as losartan, an ARB, prevented migration in
both IMA and CA VSMC. In contrast, migration to PDGF-BB depended on PDGF-β receptor
binding and was losartan-insensitive for both cell types.
The reaction between O2.- and NO generates another ROS termed peroxynitrite that
oxidizes lipoproteins and contributes to foam cell formation in atherosclerotic lesions [25].
Under physiological conditions, SODs convert O2.- to H2O2 that in turn is metabolized to H2O
by catalase and GPx [12]. In pathological conditions this enzymatic pathway may be
perturbed thereby leading to atherogenesis. The current study has for the first time revealed
that IMA VSMC possess significantly greater levels of SOD, catalase, GPx and NOS
enzymatic activities compared to their coronary counterparts. Indeed, the increase in NOS
activity was mimicked by an increase in the levels of nitrite, the stable end-product of NO, in
IMA versus CA cells. The elevated activity of NOS in IMA VSMC is critically important in
that an adequate quantity of NO is required not only to maintain normal vascular tone but also
to suppress VSMC proliferation and migration [26]. GPx, on the other hand, exerts beneficial
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functions by removing H2O2 and detoxifying the lipid hydroperoxides. A previous study
investigating glutathione-related antioxidant defenses in carotid atherosclerotic plaques of 13
patients subjected to endarterectomy and in normal IMA of 13 patients undergoing CA
bypass grafting showed that GPx was undetectable in the plaques of 7 patients and was
considerably lower in the others compared to IMA [27]. Furthermore, increased GPx, Mn-
SOD and catalase activities are associated with intracranial artery resistance to
hypercholesterolemia-induced fatty streak formation compared to extracranial arteries, in
human fetuses [28]. The significance of these data was emphasized by our findings revealing
a diminished NAD(P)H oxidase activity and thus O2.- generation in IMA versus CA VSMC.
Considering the involvement of NAD(P)H-mediated overproduction of O2.- in VSMC
migration [23], it is plausible that reduced NAD(P)H oxidase activity and thus O2.- production
may contribute significantly to the resistance of IMA to atherosclerosis.
In the present study, the involvement of O2.- production in Ang II-, PDGF-BB- or ox-LDL-
induced cell migration was investigated through O2.- scavengers, namely MnTBAP (10-50
M) and Tiron (10 M). It has been shown that while the lower concentration of MnTBAP, a
cell-permeable SOD mimetic, is sufficient to inhibit Ang II-mediated IMA VSMC migration,
higher quantities are required to inhibit those from CA in the presence of Ang II or ox-LDL.
The studies show that the previously determined effective dose of Tiron, an exogenous O2.-
scavenger, failed to suppress migratory responses in either cell type in the presence of any of
the atherogenic agents [29]. Taken together, these data imply that neutralization of
endogenous O2.- is a prerequisite for efficacious inhibition of VSMC migration and support
our findings that IMA VSMC possess higher levels of SODs thereby requiring substantially
less MnTBAP to eradicate atherogen-mediated migration. Reduced oxidative stress had no
benefit for PDGF-BB-induced migration supporting our previous work in aortic VSMC
migration studies [18]. These data confirm the results generated by losartan experiments that
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the elements which regulate PDGF-activated VSMC migration are different from those
induced by ox-LDL and Ang II.
In the current study CA and IMA VSMC migration induced by ox-LDL, PDGF-BB or Ang
II was inhibited by two statins, i.e. pravastatin and mevastatin. Statins lower cholesterol levels
and inhibit isoprenoid intermediates (GGPP and FPP) synthesis that post-translationally
modify (i.e. isoprenylate) proteins including the small GTPases Rho and Ras to facilitate lipid
attachment with resultant functional activation [30]. To identify the mechanism(s) that
account for migration-suppressive effects of statins, VSMC were microinjected with GGPP or
FPP to recover directed migration in response to ox-LDL, Ang II or PDGF-BB. FPP and
GGPP microinjection abolished inhibitory effects of statins selectively in CA and IMA
VSMC, respectively. However, while FPP-mediated recovery of CA cell chemotaxis was
independent of the atherogenic agent used, GGPP was only effective in IMA VSMC exposed
to Ang II. These findings were corroborated by experiments employing a farnesyltransferase
inhibitor (FTI) that blocks Ras/MAPK farnesylation and Y-27362, an inhibitor of Rho-kinase
that prevents geranylated Rho activating its target Rho-kinase. While FTI significantly
attenuated CA VSMC chemotaxis in the presence of Ang II or PDGF-BB, Y-27362 did not
affect the migratory ability of these cells. In contrast, Y-27362 inhibited Ang II-induced IMA
VSMC migration without affecting those stimulated by PDGF-BB. Moreover, in IMA VSMC
both inhibitors suppressed chemotaxis to PDGF-BB. This suggests that the inhibition of
HMG-CoA reductase through prevention of the isoprenylation of members of Ras and Rho
families of low-molecular-weight GTP-binding proteins and is associated with the beneficial
effects of statins. The critical roles of Rho, Ras and other small GTP-binding proteins
including p21 Rac in the assembly of NAD(P)H oxidase enzyme system, cell proliferation,
eNOS activity and thus NO generation, may shed additional light onto why IMA are
relatively resistant to macroscopic atherosclerotic plaque development [31,32].
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In conclusion, statins, free radical scavengers, ARB and ACEI may suppress the early
events in atherogenesis by markedly inhibiting VSMC migration. The signaling pathways that
are involved in statin-mediated suppression of migration appear to differ according to the
vascular tree that the VSMC originate from. The enhanced antioxidant enzyme activities
along with diminished NAD(P)H oxidase activity partially explain the resistance of human
IMA VSMC to ox-LDL-induced chemotaxis. Given the observed resistance of IMA VSMC
to ox-LDL and PDGF-BB-evoked migration, it is reasonable to suggest that the choice of a
by-pass conduit should be with a tissue source able to resist atherogenesis in the persistent
dyslipidaemic and growth factor rich environment.
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Legends
Figure 1. Migratory pattern of human CA and IMA VSMC in a gradient of ox-LDL or native
LDL. Circular histograms show the proportion of cells migrating in each direction. The arrow
indicates the mean direction of movement assessed by cyclical statistics (Rayleigh test:
p<0.01). The grey wedge indicates the 99% confidence interval for the mean.
Low levels of ox-LDL (25 g/ml) did not induce chemotaxis in CA (A) or IMA (B) VSMC.
The higher concentration of ox-LDL produced significant migration in CA VSMC (50, 75
and 100 g/ml; Fig. 1C, 1E and IG, respectively) but did not induce migration in IMA VSMC
(Fig. 1D, 1F and IH). Native LDL (100 g/ml) did not induce migration in CA (Fig. 1I) or
IMA (Fig. 1J) VSMC. n≥30 cells from 3 independent experiments were used.
Figure 2. Effects of antioxidants (Tiron and MnTBAP), receptor blockade (Losartan, CD36
and its control antibody) and angiotensin-converting enzyme inhibitor (Enalapril) on
oxidized-LDL-induced coronary artery smooth muscle cell migration. n≥30 cells from 3
independent experiments were used. *p<0.01 (Rayleigh test: chemotaxis detected); #p<0.01
(t-Test: % migrating cells vs. control).
Figure 3. (A) Effect of Ang II on IMA and CA VSMC migration. (B) Effects of antioxidants
(Tiron and MnTBAP) and Ang II type 1 receptor blocker (Losartan) on Ang II-mediated
chemotaxis. n≥30 cells from 3 independent experiments were used. *p<0.01 (Rayleigh test);
#p<0.01 (t-Test: % migration vs. cell type control).
Figure 4. (A) Effect of PDGF-BB on IMA and CA VSMC migration. (B) Effects of
antioxidants (Tiron and MnTBAP), Ang II type 1 receptor blocker (Losartan) and receptor
blockade by specific and control antibodies on PDGF-BB-mediated chemotaxis. n≥30 cells
from 3 independent experiments were used. *p<0.01 (Rayleigh test); #p<0.01 (t-Test: %
migration vs. cell type control).
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Figure 5. (A) Effect of oxidized-LDL on CA VSMC migration in the absence and presence
of isoprenoids, namely geranylgeranylpyrophosphate (GGPP) or farnesylpyrophosphate
(FPP). Effects of isoprenoids, Y-27362 (a Rho-kinase inhibitor) or FTI (a farnesyltransferase
inhibitor) on IMA and CA VSMC migration in the presence of Ang II (B) or PDGF-BB (C).
n≥30 cells from 3 independent experiments were used. *p<0.01 (Rayleigh test); #p<0.01 (t-
Test: % migration vs. cell type control); †p<0.01 (t-Test: % of migrating cells vs. statin alone
for that cell type).
